과제정보
Schematic Fig. 5A created with BioRender.com (2024).
참고문헌
- Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors; a systematic review and meta-analysis. Clin Oncol (R. Coll. Radiol). 2016. 28: 127.
- Agnello L, Camorani S, Fedele M, Cerchia L. Aptamers and antibodies: Rivals or allies in cancer targeted therapy? Explor Target Antitumor Ther. 2021. 2: 107-121.
- Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: Classification, preparation, and applications. Nanoscale Res Lett. 2013. 8: 102-102.
- Alshaer W, Hillaireau H, Vergnaud J, et al. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. J Control Release. 2018. 271: 98-106.
- Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angewandte Chemie International Edition. 2006. 45: 8149-8152.
- Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis. BMJ. 2018. 360: k793.
- Chen S, Dominik PK, Stanfield J, et al. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. J Immunother Cancer. 2021. 9: e003464. doi: 10.1136/jitc-003464.
- Conte M, De Palma R, Altucci L. HDAC inhibitors as epigenetic regulators for cancer immunotherapy. Int J Biochem Cell Biol. 2018. 98: 65-74.
- Ganson NJ, Povsic TJ, Sullenger BA, et al. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol. 2016. 137: 1610-1613.e7.
- Gao T, Mao Z, Li W, Pei R. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect. J Mater Chem B. 2021. 9: 746-756.
- Gilboa E, Berezhnoy A, Schrand B. Reducing toxicity of immune therapy using aptamer-targeted drug delivery. Cancer Immunol Res. 2015. 3: 1195-1200.
- Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017. 2: e000213-000213. eCollection 2017.
- Jain A, Maheshwari V, Alam K, Mehdi G, Sharma SC. Apoptosis in premalignant and malignant squamous cell lesions of the oral cavity: A light microscopic study. Indian J Pathol Microbiol. 2009. 52: 164-166.
- Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020. 70: 86-104.
- Kim M, Lee JS, Kim W, et al. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. J Control Release. 2022. 348: 893-910.
- Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev. 2021. 176: 113851.
- Le VKH, Pham TPD, Truong DH. Delivery systems for vorinostat in cancer treatment: An updated review. Journal of Drug Delivery Science and Technology. 2021. 61: 102334.
- Li T, Yao F, An Y, Li X, Duan J, Yang X. Novel complex of PD-L1 aptamer and holliday junction enhances antitumor efficacy in vivo. Molecules. 2021. 26: 1067. doi: 10.3390/molecules26041067.
- Li Z, Song W, Rubinstein M, Liu D. Recent updates in cancer immunotherapy: A comprehensive review and perspective of the 2018 china cancer immunotherapy workshop in beijing. J. Hematol Oncol. 2018. 11: 142-143.
- Liu B, Zhang J, Liao J, et al. Aptamer-functionalized nanoparticles for drug delivery. J Biomed Nanotechnol. 2014. 10: 3189-3203.
- Lv H, Wang T, Ma F, et al. Aptamer-functionalized targeted siRNA delivery system for tumor immunotherapy. Biomed Mater. 2022. 17: 10.1088/1748-605X/ac5415.
- Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007. 12: 1247-1252.
- Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019. 16: 563-580.
- Melosky B, Juergens R, McLeod D, et al. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer. 2019. 134: 259-267.
- Nayak A, Raikar A, Kotrashetti V, Nayak R, Shree S, Kambali S. Histochemical detection and comparison of apoptotic cells in the gingival epithelium using hematoxylin and eosin and methyl green-pyronin: A pilot study. J Indian Soc Periodontol. 2016. 20: 294-298.
- Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nano-Enabled Medical Applications. 2020. 61-91.
- Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019. 18: 175-196.
- Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell. 2018. 175: 313-326.
- Terranova-Barberio M, Thomas S, Ali N, et al. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017. 8: 114156-114172.
- West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014. 124: 30-39.
- Xu W, Siddiqui IA, Nihal M, et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials. 2013. 34: 5244-5253.
- Zheng H, Zhao W, Yan C, et al. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2016. 22: 4119-4132.